Cablivi Approved for Rare Clotting Disorder

WEDNESDAY, Feb. 6, 2019 -- Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and deadly disorder that causes blood...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news